Form D · Biotechnology

Oncothyreon Inc.

Seattle, WA · CIK 0001412067

Offering snapshot reported Aug 15, 2014 · SEC filing

Reported sold
$22.9M
Offering amount: $22.9M
Investors reported
5
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Aug 8, 2014
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Aug 15, 2014Initial$22,861,428No comparison5SEC filing
Feb 17, 2011Initial$150,000No comparison1SEC filing
Oct 6, 2010Initial$14,850,045No comparison17SEC filing
Jul 15, 2010Initial$200,000No comparison1SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
Yes
Sales commissions
$0
Finders' fees
$0
Form D file number
021-223047
The securities were issued in connection with a merger, the consideration of which was the exchange of the target's securities for issuer securities.

Source: Form D, filed Aug 15, 2014. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Gary Christianson Executive
Julia Eastland Executive
Diana Hausman Executive
Christopher Henney Director
Richard Jackson Director
Shashi K. Karan Executive
Robert L. Kirkman Director, Executive
Ted W. Love Director
Scott Peterson Executive
Daniel Spiegelman Director
W. Vickery Stoughton Director
Jay Venkatesan Executive
Douglas Williams Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
2601 Fourth Avenue Suite 500
Seattle, WA, 98121